Cycle five. Clinic three. Country two. Year four. £50,000 gone.

Nader AlSalim sat across from another fertility doctor, who delivered another probabilistic forecast: “25-40% chance this works.” No certainty. No guarantees. Just another $20,000 gamble.

His wife had endured the hormone injections, the egg retrievals, the embryo transfers, the crushing two-week waits ending in negatives. He’d watched their savings disappear into an unpredictable abyss where each failed cycle meant choosing: Try again and risk financial ruin, or give up on parenthood?

The doctors couldn’t tell him if cycle six would work. Or seven. Or ten. The fertility industry operated on a brutal economic model: pay repeatedly until you succeed or run out of money.

Most people run out of money.

This transformation represents why Gaia Family, a London and US-based fertility insurance platform, has won the 2026  Global Recognition Award for leveraging AI, achieving 90% accuracy in forecasting IVF success to create fixed-cost treatment plans with built-in protections serving couples across 57 US clinic locations, democratizing access for the 98% of fertility-needing individuals priced out by traditional models. Founded in 2019 by AlSalim following his personal journey, Gaia achieved $37+ million funding from Atomico, Valar Ventures (Peter Thiel’s firm), Kindred Capital, and Seedcamp, and developed “Gabi”—an AI analyzing millions of IVF cycles since 2003, providing personalized predictions and outcome-based insurance.

Technical Innovation and Architecture

Traditional fertility treatment operates on devastating economics: $15,000-30,000 per IVF cycle. 25-40% success rate. An unknown number of cycles is needed. Total cost? Anywhere from $15,000 to $150,000+. No one can tell you in advance.

Gaia‘s “Gabi” AI changes this completely.

The system analyzes millions of historical IVF cycles dating back to 2003—data from the UK’s Human Fertilisation & Embryology Authority containing hundreds of thousands of treatment outcomes. It processes your personal biometrics, including age, AMH levels, follicle counts, sperm parameters, and previous pregnancy history. It evaluates clinic-specific success rates. Then it predicts with 90% accuracy how many cycles you’ll likely need to achieve a live birth.

Not generic averages. Your specific probability is based on your unique profile.

The output transforms decision-making: You know your personalized success probability. You know the predicted cycle requirements. You know the estimated total cost. You know before starting what you’re actually getting into.

But Gaia goes beyond mere prediction. They build insurance around it.

The fixed-cost Gaia Plan works like this: If predictions estimate you need three cycles, you pay one predetermined price covering up to that number—regardless of actual requirements. If your first egg retrieval fails to produce viable embryos, Gaia covers another attempt at no additional cost. Once viable embryos exist, you get unlimited frozen embryo transfers (typically $5,000 each elsewhere) at no extra cost until live birth.

If all transfers fail without resulting in pregnancy, Gaia provides a refund credit toward another complete cycle—the financial risk transfers from you to Gaia’s actuarial model.

Compare this to traditional fertility treatment: Every failed cycle means deciding whether you can afford to try again. Every transfer costs another $5,000. Every setback drains savings further. Gaia eliminates that escalating nightmare.

The company partners with 57 US clinic locations across 23 groups, negotiating preferential rates and aligning incentives around successful outcomes rather than procedure volume. Traditional clinics profit from more cycles regardless of success. Gaia’s model makes reimbursement partially dependent on achieving live births, incentivizing excellence rather than repetition.

The HFEA research collaboration publishes the methodology for its predictive model transparently. It makes the prediction tool freely available on Gaia’s website—even for people who can’t afford the complete service: knowledge democratization, not proprietary black boxes.

Market Strategy and Leadership

Nader AlSalim calls himself a “very, very accidental entrepreneur.”

He didn’t exit Goldman Sachs seeking startup glory. He left because after spending £50,000 over four years watching his wife endure five IVF cycles, he couldn’t unsee the system’s cruelty.

His 14-year investment banking career—eight years as a Goldman Sachs Executive Director covering Middle East markets, Head of Middle East at VTB Capital, and Associate at Citi—provided exactly the skills needed to fix it: risk modeling, actuarial analysis, insurance product structuring, and capital markets expertise. But the motivation came from lived pain, not market opportunity.

“The pain isn’t just emotional and physical—it’s also financial,” he explains. “We were fortunate enough to have a child. Most people don’t even get there.”

That last sentence drives everything. Gaia’s mission explicitly targets “the 98% of people who need fertility treatment but can’t access it.” AlSalim’s repeated emphasis that “everyone who wants a family should have the chance to try” isn’t marketing—it’s personal conviction from someone who almost became a statistic.

The company serves everyone, with no eligibility criteria based on age or health factors, unlike competitors who exclude the highest-risk patients. It explicitly welcomes LGBTQ+ couples and single parents by choice. AlSalim rejects “femtech” framing: “This is not a woman’s issue; it is insane that people think that. This is a wider family issue.”

Investors recognized the combination of personal authenticity and technical sophistication. Kindred Capital led the 2020 $3 million seed. Atomico led the February 2022 $20 million Series A, with Partner Sasha Astafyeva stating: “A whole host of factors – from declining sperm rates to people giving birth later in life – is leading to upward pressure on demand for fertility services. Gaia’s offer is well placed to help huge numbers of families frozen out based solely on financial reasons.”

Then in January 2025, Valar Ventures—Peter Thiel’s fintech-focused firm—led a $14 million Series B. Total funding: $37+ million.

The company scaled from UK launch (2020) to 57 US locations across 23 clinic groups by 2026. Service lines expanded beyond IVF into egg freezing, egg donation, and embryo batching. In November 2025, mainstream media coverage (New York Post, Fox News) highlighting the “90% prediction accuracy” brought broader awareness beyond fertility communities.

Industry Impact and Future Vision

The statistics reveal the crisis: Fifteen percent of couples worldwide need fertility intervention, with less than 2% treatment due to cost barriers.

Average US IVF cycle: $15,000-30,000. Most couples need 2-4 cycles: $30,000-120,000+ total. Success rate per cycle: 25-40%—meaning you might succeed immediately or require ten attempts. No one knows in advance.

Only 27% of US employers offer fertility benefits, typically capped at $10,000-20,000 lifetime maximum—insufficient for complete treatment. The rest? Pay out of pocket or don’t pursue parenthood.

This creates impossible choices. Couples drain retirement accounts—Max out credit cards. Take second jobs. Then abandon treatment mid-journey when money runs out—despite remaining medically viable paths to parenthood.

Gaia’s fixed-cost model with unlimited embryo transfers eliminates the escalating financial nightmare. Couples know total commitment before starting. They budget through monthly payment plans rather than lump sums. Unsuccessful outcomes trigger financial protections instead of additional devastating bills.

The impact extends beyond individual families to systemic improvements. Outcome-based clinic contracting incentivizes evidence-based excellence rather than procedure-volume maximization. Transparent AI methodology allows independent validation, contrasting proprietary black-box competitors. Free public access to prediction tools democratizes knowledge for everyone—even non-customers.

For couples currently priced out of parenthood: The 90% prediction accuracy, unlimited embryo transfers, and outcome-based protections transform an unpredictable gamble into a manageable journey.

This recognition isn’t for incremental improvement. It’s for applying AI and insurance innovation to one of life’s most emotionally devastating financial crises. It’s for a founder who refused to accept that fertility treatment should remain the exclusive privilege of the wealthy. It’s for proving that sophisticated actuarial modeling can democratize access to parenthood dreams.

The gamble is becoming predictable. The financial abyss is becoming manageable. The 98% priced out are finding a path. Welcome to Gaia Family—winner of the 2026 Global Recognition Award.